To assess the associations of semaglutide with recurrent CUD, the study population included 8196 patients with T2D who had active medical encounters for T2D diagnosis in 12/20175/2021, were for the first time prescribed semaglutide or non-GLP1-1RA anti-diabetes medications during 12/20175/2021(index event), had a diagnosis of CUD on or before the index event, and had a diagnosis of at least one of obesity-associated comorbidities on or before the index event
Bioavailability in subjects with T2D was investigated in a separate analysis
Others may experience more discomfort in the thigh
Mohamad, K
Clinical Trial Evidence: Part 1 of the ESSENCE Study The FDAs decision is supported by part 1 of the ESSENCE trial, a multicenter, phase 3, randomized, double-blind, placebo-controlled study evaluating once-weekly semaglutide 2.4 mg in adults with biopsy-confirmed MASH and liver fibrosis (F2F3)
Featuring state-of-the-art medical equipment, this center offers patients warm medical care in a comfortable consultation area, with humanistic care and professional guidance all around